Cargando…

Novel Pharmacological Therapy in Inflammatory Bowel Diseases: Beyond Anti-Tumor Necrosis Factor

Inflammatory bowel diseases (IBDs) are chronic conditions of the gastrointestinal tract in which dysregulated immune responses cause persistent inflammation of the gut mucosa. Biologic therapy with anti-TNF blockers has revolutionized the therapeutic management of IBD for their remarkable efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pagnini, Cristiano, Pizarro, Theresa T., Cominelli, Fabio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611384/ https://www.ncbi.nlm.nih.gov/pubmed/31316377 http://dx.doi.org/10.3389/fphar.2019.00671

Ejemplares similares

Tumor Necrosis Factor’s Pathway in Crohn’s Disease: Potential for Intervention
por: Pagnini, Cristiano, et al.
Publicado: (2021)

Genetic Dissection of the Cellular Pathways and Signaling Mechanisms in Modeled Tumor Necrosis Factor–induced Crohn's-like Inflammatory Bowel Disease
por: Kontoyiannis, Dimitris, et al.
Publicado: (2002)

Probiotics and Vitamin D/Vitamin D Receptor Pathway Interaction: Potential Therapeutic Implications in Inflammatory Bowel Disease
por: Pagnini, Cristiano, et al.
Publicado: (2021)

Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors
por: Crispino, Federica, et al.
Publicado: (2023)

Anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Ramakrishna, B.S.
Publicado: (2017)

Uncovering Pathogenic Mechanisms of Inflammatory Bowel Disease Using Mouse Models of Crohn’s Disease–Like Ileitis: What is the Right Model?
por: Cominelli, Fabio, et al.
Publicado: (2017)

Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies
por: Ferraro, Sara, et al.
Publicado: (2019)

Novel and Emerging Therapies for Inflammatory Bowel Disease
por: Al-Bawardy, Badr, et al.
Publicado: (2021)

Pharmacological Basis for Use of a Novel Compound in Hyperuricemia: Anti-Hyperuricemic and Anti-Inflammatory Effects
por: Zhao, Lei, et al.
Publicado: (2021)

Intestinal Macrophage Autophagy and its Pharmacological Application in Inflammatory Bowel Disease
por: Zheng, Yang, et al.
Publicado: (2021)

Pharmacological Therapies and Their Clinical Targets in Irritable Bowel Syndrome With Diarrhea
por: Colomier, Esther, et al.
Publicado: (2021)

Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease
por: Duan, Linshan, et al.
Publicado: (2021)

Inflammatory Bowel Disease and Risk of Colorectal Cancer: An Overview From Pathophysiology to Pharmacological Prevention
por: Lucafò, Marianna, et al.
Publicado: (2021)

A Series of Genes for Predicting Responses to Anti-Tumor Necrosis Factor α Therapy in Crohn’s Disease
por: Nie, Kai, et al.
Publicado: (2022)

Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
por: Na, Soo-Young, et al.
Publicado: (2022)

Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond
por: Di Paolo, Antonello, et al.
Publicado: (2021)

Anti-Inflammatory Medicinal Plants of Bangladesh—A Pharmacological Evaluation
por: Akhtar, Most. Afia
Publicado: (2022)

Fatal infections in older patients with inflammatory bowel disease on anti-tumor necrosis factor therapy
por: Lee, Way-Seah, et al.
Publicado: (2017)

Association of Anti–Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease
por: Cohen-Mekelburg, Shirley, et al.
Publicado: (2021)

Potential Novel Strategies for the Treatment of Dental Pulp-Derived Pain: Pharmacological Approaches and Beyond
por: Schuh, Christina M. A. P., et al.
Publicado: (2019)

Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study)
por: Alrashed, Fatema, et al.
Publicado: (2023)

Atherosclerosis Is an Inflammatory Disease which Lacks a Common Anti-inflammatory Therapy: How Human Genetics Can Help to This Issue. A Narrative Review
por: Fava, Cristiano, et al.
Publicado: (2018)

Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
por: Marsal, Jan, et al.
Publicado: (2022)

Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease
por: Nawaz, Ahmad, et al.
Publicado: (2023)

Identification of Tumor Necrosis Factor-Alpha (TNF-α) Inhibitor in Rheumatoid Arthritis Using Network Pharmacology and Molecular Docking
por: Bai, Liang Liang, et al.
Publicado: (2021)

The Pharmacological Targets and Clinical Evidence of Natural Products With Anti-hepatic Inflammatory Properties
por: Peng, Jinghua
Publicado: (2018)

The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Fousekis, Fotios S., et al.
Publicado: (2022)

Like Cures Like: Pharmacological Activity of Anti-Inflammatory Lipopolysaccharides From Gut Microbiome
por: Lin, Tzu-Lung, et al.
Publicado: (2020)

Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients
por: Lew, Daniel, et al.
Publicado: (2017)

Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children’s immunity
por: Lee, Ko Eun, et al.
Publicado: (2019)

Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
por: Billmeier, Ulrike, et al.
Publicado: (2016)

Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
por: Park, Jihye, et al.
Publicado: (2021)

Placebo and nocebo effects and mechanisms associated with pharmacological interventions: an umbrella review
por: Frisaldi, Elisa, et al.
Publicado: (2023)

REV-ERB activation as a novel pharmacological approach for treating inflammatory pain
por: Makhija, Sangeet, et al.
Publicado: (2023)

Gaseous Mediators as a Key Molecular Targets for the Development of Gastrointestinal-Safe Anti-Inflammatory Pharmacology
por: Danielak, Aleksandra, et al.
Publicado: (2021)

Integrative network pharmacology and experimental verification to reveal the anti-inflammatory mechanism of ginsenoside Rh4
por: To, Kwang-Il, et al.
Publicado: (2022)

Microbial-Based Therapies in the Treatment of Inflammatory Bowel Disease – An Overview of Human Studies
por: Basso, Paulo José, et al.
Publicado: (2019)

Alterations and Potential Applications of Gut Microbiota in Biological Therapy for Inflammatory Bowel Diseases
por: Pu, Dan, et al.
Publicado: (2022)

Salvia miltiorrhiza Bge. (Danshen) for Inflammatory Bowel Disease: Clinical Evidence and Network Pharmacology-Based Strategy for Developing Supplementary Medical Application
por: Zhang, Siyuan, et al.
Publicado: (2022)

Editorial: Cytokines and Intestinal Mucosal Immunity
por: Pizarro, Theresa T., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9sjk85a7qaospos0fihovbunc1